USPTO Examiner MILLER DALE R - Art Unit 1693

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19186434PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITISApril 2025October 2025Allow510YesNo
18978008USE OF OLEANOLIC ACID-28-O-BETA-D-GLUCOPYRANOSIDE IN PREPARATION OF ANTI-COLITIS DRUGDecember 2024September 2025Allow920YesNo
18960884PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITISNovember 2024October 2025Allow1130YesNo
18792077COLON-TARGETED ACTIVE AGENT DELIVERY CARRIER AND USES THEREOFAugust 2024June 2025Allow1030YesNo
18765449PREBIOTIC COMPOSITIONS AND METHODS OF PRODUCTION THEREOFJuly 2024August 2025Abandon1310NoNo
18680557AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSESMay 2024June 2025Abandon1310NoNo
18654457USE OF CHONDROITIN SULFATE FOR RELIEVING OCULAR PAINMay 2024August 2025Allow1520YesNo
18641536COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIESApril 2024September 2025Allow1720YesNo
18609604TREATMENT OF HEARING LOSSMarch 2024October 2024Allow700NoNo
18687295PHARMACEUTICAL COMPOSITIONFebruary 2024March 2025Allow1220YesNo
18584219OPHTHALMIC SOLUTIONSFebruary 2024October 2025Abandon2030NoNo
18430551FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYEFebruary 2024December 2025Abandon2220NoNo
18424626PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITISJanuary 2024March 2025Allow1321YesNo
18420540METHODS OF SELECTIVELY MODULATING GASTROINTESTINAL MICROBIAL GROWTHJanuary 2024April 2025Allow1520YesNo
18417312LIQUID COMPOSITION COMPRISING GLUCOSEJanuary 2024August 2024Allow700YesNo
18397012COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONSDecember 2023January 2025Abandon1310YesNo
18528550Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorlylase Inhibitors In Combination With RadiationDecember 2023March 2025Allow1510NoNo
18527321GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTSDecember 2023January 2025Abandon1310NoNo
18522850BODY MILKNovember 2023September 2024Allow1020YesNo
18521467PROCESS FOR EFFICIENT CROSS-LINKING OF HYALURONIC ACIDNovember 2023June 2025Allow1920NoNo
18504043NUTRITIONAL COMPOSITIONS WITH MFGM AND CERTAIN HUMAN MILK OLIGOSACCHARIDES AND USES THEREOFNovember 2023February 2025Allow1610YesNo
18555982USE OF CHONDROITIN SULFATE FOR RELIEVING OCULAR PAINOctober 2023March 2025Allow1720YesNo
18378985PERITONEAL DIALYSIS SOLUTIONOctober 2023October 2024Allow1210NoNo
18476119METHODS AND COMPOSITIONS FOR EXTENDING LIFESPANSeptember 2023November 2024Abandon1410NoNo
18237659METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVELAugust 2023November 2024Abandon1410NoNo
18277642MODIFIED GUANINESAugust 2023March 2026Allow3100YesNo
18362656COMPOSITE VITAMIN COMPOSITION PROMOTING GASTROINTESTINAL SYSTEM MOTILITYJuly 2023April 2025Allow2110YesNo
18274166CONJUGATES WITH INHIBITORY RECEPTOR LIGANDS TO INDUCE ANERGY IN INSULIN-BINDING B CELLSJuly 2023July 2024Allow1200YesNo
18336419NOVEL PARENTERAL CARBAMAZEPINE FORMULATIONJune 2023October 2024Abandon1610NoNo
18329047NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES AND NUCLEOTIDES AND USES THEREOF FOR TREATING AND/OR PREVENTING ENTERIC VIRAL INFECTIONJune 2023December 2025Allow3020YesNo
18033866INJECTABLE COMPOSITION AND USE OF SAID COMPOSITIONApril 2023March 2026Allow3510YesNo
18301874Senolytic Compositions and Uses ThereofApril 2023January 2026Abandon3301NoNo
18031420CHEMICAL COMPOUND COMPRISING A TRIAZINE GROUP AND METHOD FOR PRODUCING SAMEApril 2023January 2026Allow3400YesNo
18132332ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMDApril 2023February 2025Allow2220YesNo
18131161TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSEApril 2023October 2024Allow1910YesNo
18130475TREATMENT OF ALPHAVIRUS-INDUCED INFLAMMATIONApril 2023January 2025Abandon2210NoNo
18027732OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USEMarch 2023December 2025Allow3300YesNo
18245658TOPICAL ANTIVIRAL COMPOSITIONS COMPRISING HYALURONIC ACID AND CARRAGEENANMarch 2023February 2026Allow3510NoNo
18181653NUTRITIONAL COMPOSITION FOR IMPROVING CELL MEMBRANESMarch 2023June 2025Abandon2720NoNo
18044384New fluorinated hexosesMarch 2023December 2025Allow3310YesNo
18176631GLYCOCONJUGATION PROCESSMarch 2023October 2024Allow2010YesNo
18017013UTILIZATION OF VITAMIN B12 IN INHIBITING RENAL DISORDERJanuary 2023January 2026Abandon3610NoNo
18016245OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USEJanuary 2023November 2025Allow3400YesNo
17983992COMPOSITIONS COMPRISING AT LEAST ONE N-ACETYLATED AND AT LEAST ONE FUCOSYLATED OLIGOSACCHARIDE FOR USE IN THE PROMOTION OF DIGESTIVE CAPACITY IN INFANTS AND YOUNG CHILDRENNovember 2022September 2024Allow2210NoNo
17978214SENSITIVE OLIGONUCLEOTIDE SYNTHESIS USING SULFUR-BASED FUNCTIONS AS PROTECTING GROUPS AND LINKERSNovember 2022December 2025Allow3810YesNo
17977034METHOD AND COMPOSITION FOR IMPROVED HYDRATION IN ANIMALSOctober 2022January 2026Abandon3910NoNo
17920720OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING VIRAL INFECTIONSOctober 2022February 2026Allow4010YesNo
17913545METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING FIBROSIS RESULTING FROM A CORONAVIRUS INFECTIONSeptember 2022February 2026Abandon4010NoNo
17941487PHARMACEUTICAL COMPOSITION FOR INHIBITING POSTOPERATIVE ADHESIONSSeptember 2022November 2025Abandon3810NoNo
17802806Use of Albiflorin in Treatment of Coronavirus PneumoniaAugust 2022October 2025Abandon3710NoNo
17802716METHODS OF IMPROVING BONE HEALTHAugust 2022January 2026Abandon4110NoNo
17801337IMMUNOMODULATING IMINE-OXAZOLINE AZALIDESAugust 2022January 2026Abandon4120NoNo
17800584ANTI-OBESITY COMPOSITION AND COMPOSITION FOR ORAL ADMINISTRATIONAugust 2022October 2025Allow3810YesNo
17798270COMPOSITION COMPRISING 2'-FL AND DFL FOR USE IN A METHOD FOR REDUCING PAINAugust 2022September 2025Allow3800NoNo
17882412PHARMACEUTICAL COMBINATION HAVING POTENT ANTIVIRAL ACTIVITY AGAINST SINGLE-STRANDED RNA VIRUSES INCLUDING CORONAVIRUSES AND MONKEYPOXAugust 2022January 2026Abandon4110NoNo
17760102GLUCOSE IN SOLID FORM AND PROCESS FOR MANUFACTURING GLUCOSE IN SOLID FORMAugust 2022November 2025Allow4010NoNo
17859071PHOTOISOMERIZED COMPOSITIONS OF ANTHOCYANINS AND METHODS OF MAKING AND USE THEREOFJuly 2022March 2026Allow4420YesNo
17756832COMPOSITIONS FOR USE IN THE REDUCTION OF PAIN AND/OR PERCEPTION OF PAIN IN INFANTS AND YOUNG CHILDRENJune 2022September 2025Allow4010NoNo
17831535ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASEJune 2022November 2025Abandon4210NoNo
17804679IMMUNOGENIC COMPOSITIONMay 2022June 2024Allow2520YesNo
17780869MIXTURE OF HMOsMay 2022November 2025Abandon4110NoNo
17749876COMPOSITIONS AND METHODS FOR TREATING FACIAL VOLUME DEFECTSMay 2022February 2026Abandon4501NoNo
17772994IIMPROVED APPROACH TO REPAIR TISSUE DEFECTS BY BONDING INJECTABLE GELS TO NATIVE SOFT TISSUESApril 2022October 2025Allow4210YesNo
17772291ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMDApril 2022January 2025Allow3320NoNo
17729711METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONSApril 2022November 2025Allow4310NoNo
17765784MEDIUM ADDITIVE FOR SUSPENSION CULTURE, MEDIUM COMPOSITION AND CULTURE METHODMarch 2022August 2025Allow4010YesNo
17765059TREHALOSE FORMULATIONS AND USES THEREOFMarch 2022March 2025Allow3600NoNo
17763136Hydrogel Composition For Tissue Regeneration, And Support Prepared Using SameMarch 2022October 2025Abandon4310NoNo
17676675METHOD FOR DEACETYLATION OF BIOPOLYMERSFebruary 2022March 2025Allow3600YesNo
17633869a-GLUCOSIDASE INHIBITOR, INVERTASE INHIBITOR, AND SUGAR ABSORPTION INHIBITORFebruary 2022June 2025Abandon4010NoNo
17592691INHALED IVERMECTINFebruary 2022September 2025Allow4440YesNo
17586381XYLOOLIGOSACCHARIDE AS A MULTIFUNCTIONAL PREBIOTICJanuary 2022May 2025Abandon4010NoNo
17630313Antifungal composition comprising natamycin and at least one insecticideJanuary 2022August 2025Allow4210YesNo
17628857TREATMENT COMPRISING SGLT INHIBITORSJanuary 2022June 2025Abandon4110NoNo
17625394FOOD COMPOSITIONJanuary 2022June 2025Abandon4110NoNo
17567945Application of Sulfated Polysaccharides in Resisting novel CoronavirusJanuary 2022August 2025Allow4310YesNo
17565201HYDROGELS HAVING TUNABLE CROSS-LINKING DENSITIES AND REVERSIBLE PHASE TRANSITIONS AND METHODS FOR THEIR USEDecember 2021October 2025Abandon4510NoNo
17623716HYDROGEL COMPOSITIONS AND USES THEREOFDecember 2021August 2025Allow4401NoNo
17621938COMPOSITIONS AND METHODS FOR MODULATING MICROBIOMESDecember 2021December 2025Allow4820YesNo
17621248FUNCTIONAL FOODDecember 2021July 2025Abandon4210NoNo
17615479HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT OF SYMPTOMS IN A PATIENT SUFFERING FROM NON-COELIAC WHEAT AND / OR GLUTEN SENSITIVITYNovember 2021January 2025Abandon3800NoNo
17611847MEDICAMENT AND COMBINATION PRODUCT USED FOR PREVENTING, ALLEVIATING AND/OR TREATING FIBROSIS, AND USE THEREOFNovember 2021October 2025Abandon4720NoNo
17610951USE OF GINSENOSIDE M1 FOR TREATING CANCERNovember 2021February 2025Abandon3910NoNo
17608837CHLORIDE INTRACELLULAR CHANNEL 1 FOR REGULATION OF FOOD INTAKENovember 2021March 2025Allow4010YesNo
17608203COMPOUND FOR REGULATING BODY WEIGHT IMBALANCE, COMPOSITION THEREOF AND APPLICATION THEREOFNovember 2021January 2025Allow3910NoNo
17606313NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASESOctober 2021January 2025Allow3910YesNo
17605900CELLULOSE NANOCRYSTAL COMPOSITE AND METHOD FOR PRODUCING THE SAMEOctober 2021December 2025Abandon5020NoNo
17506227GLUCOSE INFUSION SOLUTION COMPOSITIONOctober 2021June 2025Allow4340NoNo
17498200Edible Energy CompositionOctober 2021February 2026Allow5220NoNo
17438712METHODS OF TREATING ACUTE CORONARY SYNDROMESSeptember 2021November 2025Allow5030YesNo
17472604AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSESSeptember 2021April 2024Allow3140YesNo
17435629METHOD AND KIT FOR DETECTING INFLUENZA VIRUS, AND METHOD FOR DIAGNOSING INFLUENZA VIRUS INFECTIONSeptember 2021April 2025Allow4310NoNo
17369791CYCLODEXTRIN DIMERS AND USES THEREOFJuly 2021February 2026Allow5641YesNo
17419068BRAIN-PENETRATING LIGAND AND DRUG CARRIERJune 2021October 2024Allow4010YesNo
17418570HEAT STRESS RELIEVING AGENTJune 2021April 2025Abandon4620NoNo
17417049COMPOSITION AND METHOD FOR PROMOTING INTESTINAL BARRIER HEALINGJune 2021November 2024Abandon4110NoNo
17416573A NUTRITIONAL COMPOSITION COMPRISING A COMBINATION OF HUMAN MILK OLIGOSACCHARIDES TO IMPROVE THE GASTROINTESTINAL BARRIERJune 2021December 2025Allow5450YesNo
17292963CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNAMay 2021February 2025Allow4510YesNo
17291481METHODS OF SUPPORTING GASTROINTESTINAL HOMEOSTASISMay 2021November 2024Allow4210YesNo
17286803PHARMACEUTICAL USE OF ANEMOSIDE B4 AGAINST ACUTE GOUTY ARTHRITISApril 2021January 2025Allow4520NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MILLER, DALE R.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
1.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MILLER, DALE R - Prosecution Strategy Guide

Executive Summary

Examiner MILLER, DALE R works in Art Unit 1693 and has examined 52 patent applications in our dataset. With an allowance rate of 73.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner MILLER, DALE R's allowance rate of 73.1% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by MILLER, DALE R receive 2.15 office actions before reaching final disposition. This places the examiner in the 58% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MILLER, DALE R is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +44.1% benefit to allowance rate for applications examined by MILLER, DALE R. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 34.4% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 34.8% of cases where such amendments are filed. This entry rate is in the 52% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 88% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 142.9% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.